The diaTribe Foundation invites you to the 3rd Annual Musings Under the Moon: Next-Gen Diabetes.
Join us on Monday, June 25, 2018 from 9:30pm–1:30am at BB King's Blues Club to hear the brightest and most innovative leaders in diabetes technology and therapy share their insights and ideas on the future of the field. The diaTribe Foundation's Kelly Close and Adam Brown will lead this fascinating discussion with a panel of experts in the diabetes field. Along with forward-thinking dialogue, this event will feature live music and great mingling.
9:00pm – Doors Open for Live Music, Bites, & Libations
9:30pm – Discussions on Next-Gen Diabetes, moderated by Adam Brown and Kelly Close, followed by attendee Q&A.
12am–1:30am – Stay after hours for continued conversation and mingling, including a "Fireside Chat" with Livongo leader Manny Hernandez, live music, and refreshments.
Immediately preceding Musings Under the Moon, The diaTribe Foundation and TCOYD invite you to join us at the 12th Annual Diabetes Forum for sophisticated camaraderie and cutting-edge opinions from leading experts in diabetes. For more information and to purchase tickets, please visit the event page here.
We look forward to seeing you on Monday, June 25! Please spread the word and share this event with anyone interested in learning more about diabetes and getting smarter about the newest updates in the field. We thank you for your support of The diaTribe Foundation and all people with diabetes.
Vice President, Clinical and Medical Affairs, Bigfoot Biomedical, Inc.
Jennifer Block is the Vice President of Clinical and Medical Affairs at Bigfoot Biomedical, Inc. A nurse practitioner and certified diabetes educator, Jennifer has worked in almost all areas of diabetes care — from clinical research to patient education to industry.
Jennifer Block brings twenty years of experience in diabetes care and clinical research. As a Nurse Practitioner and Certified Diabetes Educator, Jen has worked to empower people to live well with diabetes. Jen spent over 15 years working as a research coordinator for clinical trials primarily focused on novel diabetes devices including continuous glucose monitors, and a myriad of artificial pancreas systems at Stanford University Medical Center. Jen is passionate about the translation of experience gained in clinical research into advances in clinical care and education.
Prior to joining the team at Bigfoot Biomedical, Jen served as a consultant to a number of diabetes care companies and organizations, including Tandem, Insulet, Dexcom, Becton Dickinson, Abbott Diabetes Care, Unomedical, and Lifescan. Jen leverages her experience in education, clinical care, research, and industry to find innovative ways to evaluate novel therapies, improve diabetes care, and reduce the burdens of diabetes for everyone whose life is touched by this challenging disease.
North American Head of Diabetes and Cardiovascular, Sanofi
As the North America Head of Diabetes and Cardiovascular for Sanofi, Michelle Carnahan leads all commercial operations for the Business Unit in the U.S. (including Puerto Rico) and Canada, which is comprised of Sales, Marketing, Market Access, One Trade, Innovative Solutions and Business Operations Support.
Michelle has a broad commercial background which includes substantial P&L accountability, extensive partnerships, significant organizational results, and strategic innovation work. Throughout her career, she has demonstrated her skills as a passionate, patient-centric leader who consistently holds herself and the organization to drive outcomes and better experiences for patients. She joined Sanofi in January 2018, bringing deep knowledge across many therapeutic areas including CNS, women’s health, musculoskeletal and diabetes. During her 25 years with Eli Lilly, she held progressively more senior roles in sales, marketing, human resources, and general management. Most recently, Michelle served as Chief Operating Officer for the International Business of Lilly, where she was responsible to drive the commercial operations and strategy.
Michelle is recognized for championing women’s issues and education. She served as executive sponsor of Lilly’s Women’s Leadership Network for several years. She also served as a member of the Advisory Council for St. Mary’s Child Center, is currently an Advisor to the JBW Women in Management Center at Purdue University, and serves on the Alumni Board at DePauw University.
Michelle earned her Bachelor of Arts in Economics from DePauw University.
Divisional VP and Commercial Lead, EU, Africa, & Middle East, Abbott Diabetes Care
Sophie Dutilloy is a Divisional Vice President and Commercial Lead for Abbott Diabetes Care, overseeing Freestyle Libre/Freestyle operations in the EU, Africa, the Middle East, and Pakistan, based in Wiesbaden, Germany. She joined Abbott in January 2016 to lead the commercialization of FreeStyle Libre, a revolutionary device that enables people with diabetes to monitor their glucose levels without routine fingersticks, and enjoy a healthier, fuller life.
Sophie also co-chairs the Women Leaders Of Abbott executive committee in Europe with the objective to accelerate the development and advancement of women at all levels of the organization.
After graduating from the Fuqua School of Business Administration at Duke University in Durham, North Carolina, Sophie began her career in Healthcare working for Johnson & Johnson in Consumer Products and Medical Devices across portfolios ranging from skin care products, contact lenses to hospital surgical devices, in Canada, US and UK.
Throughout her 23-year career, Sophie has worked closely with medical professionals in various roles in Marketing, Sales Leadership and General Management across North America and EMEA. Sophie’s leadership was recently recognized by the Healthcare Businesswomen’s Association (HBA) when she was named a 2018 HBA Rising Star.
Senior Vice President, Data, Dexcom
Annika Jimenez joined Dexcom in 2015 as Senior Vice President, Data, bringing with her a deep and vast knowledge of next-generation data architectures and technologies. As SVP, she is driving the forward evolution of Dexcom’s data capabilities while also putting its CGM-originated data at the center of a rich and growing diabetes data ecosystem.
Prior to joining Dexcom, Annika held several leadership roles in Silicon Valley. As Vice President at Pivotal, Inc., she oversaw the development and management of the world-renowned Data Science, Data Architecture and Data Engineering services organization. She also served as Senior Director at Yahoo! for multiple divisions, where she was instrumental in driving the company’s data capabilities into international markets and bringing numerous data-driven products to market.
Her distinguished contributions have also led to frequent speaking engagements at large industry events, including Strata, Data Science Summit, the White House - Data to Knowledge to Action, EMC World, and others. Annika earned a Master of Pacific and International Affairs from the University of California, San Diego School of Global Policy and Strategy and her Bachelor of Arts in Spanish and Math from the University of California, Davis.
President & COO, Insulet
Shacey Petrovic is the President and Chief Operating Officer of Insulet Corporation. Previously, she served as its Executive Vice President and President of Diabetes Products and as the Chief Commercial Officer. Prior to Insulet, she served as a Senior Advisor at Pritzker Group Private Capital and worked closely with the healthcare investment team. She also served two years as the Chief Executive Officer and President of Clinical Innovations, LLC.
She joined Clinical Innovations from Hologic, where she served as Vice President and General Manager of its gynecologic surgical division. As Hologic's Vice President of global surgical marketing, she led a direct-to-consumer advertising campaign and the integration of Interlace Medical. She has execution skills and a proven ability to grow product lines and lead top performing teams. Prior to her tenure with Hologic, she served in sales and marketing leadership roles in the United States and Europe for Cytyc Corporation. She served in a number of key roles during 13 years at Hologic, Inc. and Cytyc Corporation.
Shacey’s 15 years of progressive leadership in the healthcare industry includes global successes in new business development as well as product and market launches. She has a long track record of success within commercial operations, including new product introduction, market share growth and business development. She is a seasoned expert with nearly two decades of experience in the medical device industry. She earned her B.S. in Biology from the University of Wisconsin.
Vice President, Connected Care and Site Head, Cambridge Innovation Center, Lilly
Marie Schiller is the Vice President of Connected Care and the Site Head of Lilly’s Cambridge Innovation Center. Prior to joining Lilly, Marie served as Principal of Schiller Advisors and Partner Emeritus at Health Advances where she served as a business advisor in drug delivery innovation and integrated care models to senior management and board of directors at early-stage companies, biopharma and medtech companies, non-profit organizations, and investment firms.
She was previously involved as Managing Director and Partner at Health Advances where she created and led the diabetes and drug delivery consulting practice for 15+ years.
In addition, Marie has been integrally involved with the T1D Exchange, an initiative funded by The Helmsley Charitable Trust focused on accelerating outcomes for people with type 1 diabetes. Marie has a Bachelor of Arts degree in Chemistry from the University of Vermont. On a personal note, she is committed to bringing better solutions to people with diabetes and chronic diseases motivated in part by her personal 33-year history with type 1 diabetes.
General Manager of MDI Solutions, Medtronic Diabetes
Laura Stoltenberg is the General Manager of MDI Solutions at Medtronic Diabetes; she previously ran the type 2 business (non-intensive diabetes therapies). Prior to joining Medtronic, Laura served as Founder and Principal of business consulting firm Vitae Advisors, LLC, CCO of Exact Sciences, and VP at GE Healthcare, where she managed the Lunar business.
Business Leader with record of achievement in commercial, business development and general management roles. Proven corporate entrepreneur with ability to synthesize information into actionable strategies that align with business goals. Recognized for ability to assess market needs and develop diverse, high-performing teams to execute product and channel development strategies to achieve global growth initiatives.
As an executive in medical devices, life sciences and health care IT industries, she has a deep understanding of screening and diagnostic solutions. She has experience with many stakeholders including the FDA, Medicare, private payers, renown researchers, physician and patient advocacy groups. Having sold globally to hospitals, clinics and primary care physicians, she understands cultural differences in health care and decision making. Her teams have developed products and implemented programs that demonstrate improved clinical and economic outcomes. She gets excited about innovative growth strategies. As an example, GE Lunar launched the very first GE Healthcare direct-to-consumer product and spearheaded innovative wellness strategies.
Executive Vice President, Commercial Strategy & Corporate Affairs, Novo Nordisk
Camilla Sylvest joined Novo Nordisk in 1996 as trainee. From 1997 to 2008, Camilla had roles in headquarters and regions within pricing, health economics, marketing and sales effectiveness. In 2003, she was appointed vice president of sales and marketing effectiveness in Region Europe. From 2008 to 2015, Camilla headed up affiliates and business areas of growing size and complexity in Europe and Asia and in 2013 she was also appointed corporate vice president. In 2015, Camilla was appointed senior vice president and general manager of Novo Nordisk’s Region China. In this role she was responsible for the company’s activities in China, Taiwan and Hong Kong. In October 2017, Camilla was promoted to executive vice president and member of Executive Management in Novo Nordisk.
Camilla serves as a member of the board of Danish Crown A/S, Denmark.
Camilla holds an MSc in Economics from University of Southern Denmark and an Executive MBA from Scandinavian International Management Institute.